Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: Data from CHARM and ADHERE

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 10, 2013, Pages 1236-1247

  Panaccione, R ^a   Colombel, J F ^b   Sandborn, W J ^c   D'Haens, G ^d,e   Zhou, Q ^f   Pollack, P F ^f   Thakkar, R B ^f   Robinson, A M ^f  

^a UNIVERSITY OF CALGARY   (Canada)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e Imelda GI Clinical Research Center   (Belgium)

^f ABBVIE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; MERCAPTOPURINE; METHOTREXATE; PLACEBO;

ABDOMINAL ABSCESS; ARTICLE; BASAL CELL CARCINOMA; BREAST CANCER; BRONCHITIS; CANDIDIASIS; CELLULITIS; COLON CANCER; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FATTY LIVER; FISTULA; GASTROENTERITIS; HEPATITIS; HUMAN; INCIDENCE; INDUCTION CHEMOTHERAPY; INTESTINAL ABSCESS; KIDNEY CARCINOMA; LIMB ABSCESS; LIVER CANCER; LIVER CELL CARCINOMA; LIVER FUNCTION TEST; LOBAR PNEUMONIA; LOWER RESPIRATORY TRACT INFECTION; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCLE ABSCESS; OPEN STUDY; PERIANAL ABSCESS; PERINEAL ABSCESS; PERITONITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; SEPSIS; SIDE EFFECT; SINUSITIS; SKIN CANCER; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION; URINARY TRACT INFECTION; UTERINE CERVICITIS; VULVAL CANCER;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; DOUBLE-BLIND METHOD; GLUCOCORTICOIDS; HUMANS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84885956038     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12499     Document Type: Article

References (19)

1. Cho JH,. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol 2008; 8: 458-66.
2. Carbonnel F, Jantchou P, Monnet E, Cosnes J,. Environmental risk factors in Crohn's disease and ulcerative colitis: an update. Gastroenterol Clin Biol 2009; 33 (Suppl. 3): S145-57.
3. van Deventer SJ,. Review article: targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease-the mechanisms of action of infliximab. Aliment Pharmacol Ther 1999; 13 (Suppl. 4): 3-8.
4. Colombel JF, Rutgeerts PJ, Sandborn WJ, et al,. Adalimumab induces deep remission in patients with Crohn's disease. Clin Gastroenterol Hepatol 2013 [Epub ahead of print].
5. Colombel JF, Sandborn WJ, Rutgeerts P, et al,. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65.
6. Sandborn WJ, Rutgeerts P, Enns R, et al,. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829-38.
7. Hanauer SB, Sandborn WJ, Rutgeerts P, et al,. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-33.
8. Sandborn WJ, Hanauer SB, Rutgeerts P, et al,. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56: 1232-9.
9. Rutgeerts P, Van Assche G, Sandborn WJ, et al,. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012; 142: 1102-11.
10. Panaccione R, Colombel JF, Sandborn WJ, et al,. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. Aliment Pharmacol Ther 2010; 31: 1296-309.
11. Colombel JF, Schwartz DA, Sandborn WJ, et al,. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 2009; 58: 940-8.
12. Kamm MA, Hanauer SB, Panaccione R, et al,. Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease. Aliment Pharmacol Ther 2011; 34: 306-17.
13. Oussalah A, Danese S, Peyrin-Biroulet L,. Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: a systematic review. Curr Drug Targets 2010; 11: 156-75.
14. Sandborn WJ, Colombel JF, Schreiber S, et al,. Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis 2011; 17: 141-51.
15. Sandborn WJ, Colombel JF, D'Haens G, et al,. Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease. Curr Med Res Opin 2013; 29: 483-93.
16. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP,. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013; 72: 517-24.
17. Schreiber S, Reinisch W, Colombel JF, et al,. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. J Crohns Colitis 2013; 7: 213-21.
18. Louis E, Mary JY, Vernier-Massouille G, et al,. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012; 142: 63-70.
19. Pariente B, Cosnes J, Danese S, et al,. Development of the Crohn's disease digestive damage score, the Lemann score. Inflamm Bowel Dis 2011; 17: 1415-22.